ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more
ANI Pharmaceuticals Inc (ANIP) - Net Assets
Latest net assets as of December 2025: $540.72 Million USD
Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has net assets worth $540.72 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.44 Billion) and total liabilities ($899.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $540.72 Million |
| % of Total Assets | 37.54% |
| Annual Growth Rate | 21.8% |
| 5-Year Change | 50.73% |
| 10-Year Change | 218.73% |
| Growth Volatility | 66.39 |
ANI Pharmaceuticals Inc - Net Assets Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual net assets of ANI Pharmaceuticals Inc from 1998 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $540.72 Million | +26.18% |
| 2024-12-31 | $428.53 Million | -6.35% |
| 2023-12-31 | $457.60 Million | +35.17% |
| 2022-12-31 | $338.54 Million | -5.63% |
| 2021-12-31 | $358.74 Million | +83.31% |
| 2020-12-31 | $195.70 Million | -8.03% |
| 2019-12-31 | $212.79 Million | +7.87% |
| 2018-12-31 | $197.26 Million | +12.88% |
| 2017-12-31 | $174.76 Million | +3.01% |
| 2016-12-31 | $169.65 Million | +5.98% |
| 2015-12-31 | $160.08 Million | +14.52% |
| 2014-12-31 | $139.78 Million | +241.26% |
| 2013-12-31 | $40.96 Million | +45.38% |
| 2012-12-31 | $28.18 Million | -25.49% |
| 2011-12-31 | $37.82 Million | +97.50% |
| 2010-12-31 | $19.15 Million | +20.95% |
| 2009-12-31 | $15.83 Million | +14.49% |
| 2008-12-31 | $13.83 Million | -53.49% |
| 2007-12-31 | $29.73 Million | +64.49% |
| 2006-12-31 | $18.07 Million | +165.02% |
| 2005-12-31 | $6.82 Million | -57.17% |
| 2004-12-31 | $15.92 Million | +83.33% |
| 2003-12-31 | $8.68 Million | +87.83% |
| 2002-12-31 | $4.62 Million | +14.12% |
| 2001-12-31 | $4.05 Million | +90.60% |
| 2000-12-31 | $2.13 Million | -61.00% |
| 1999-12-31 | $5.45 Million | +107.13% |
| 1998-12-31 | $2.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ANI Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1230278200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $1.03 Million | 0.19% |
| Other Components | $562.79 Million | 104.08% |
| Total Equity | $540.72 Million | 100.00% |
ANI Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kohl's Corporation
NYSE:KSS
|
$1.41 Billion |
|
Perrigo Company PLC
NYSE:PRGO
|
$1.41 Billion |
|
MAKINO MILLG MACH.
F:95B
|
$1.41 Billion |
|
Banpu Public Company Limited
BK:BANPU
|
$1.41 Billion |
|
Guangdong Shenling Environmental Systems Co. Ltd.
SHE:301018
|
$1.41 Billion |
|
Guangzhou Baiyun International Airport Co Ltd
SHG:600004
|
$1.41 Billion |
|
Arcplus Group PLC
SHG:600629
|
$1.41 Billion |
|
IBF Financial Holdings Co Ltd
TW:2889
|
$1.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANI Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 428,530,000 to 540,724,000, a change of 112,194,000 (26.2%).
- Net income of 78,337,000 contributed positively to equity growth.
- Dividend payments of 1,157,000 reduced retained earnings.
- Share repurchases of 12,209,000 reduced equity.
- Other comprehensive income decreased equity by 4,311,000.
- Other factors increased equity by 51,534,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $78.34 Million | +14.49% |
| Dividends Paid | $1.16 Million | -0.21% |
| Share Repurchases | $12.21 Million | -2.26% |
| Other Comprehensive Income | $-4.31 Million | -0.8% |
| Other Changes | $51.53 Million | +9.53% |
| Total Change | $- | 26.18% |
Book Value vs Market Value Analysis
This analysis compares ANI Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 273.33x to 2.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.27 | $74.28 | x |
| 1999-12-31 | $39.70 | $74.28 | x |
| 2000-12-31 | $13.30 | $74.28 | x |
| 2001-12-31 | $22.49 | $74.28 | x |
| 2002-12-31 | $22.18 | $74.28 | x |
| 2003-12-31 | $28.32 | $74.28 | x |
| 2004-12-31 | $33.43 | $74.28 | x |
| 2005-12-31 | $12.66 | $74.28 | x |
| 2006-12-31 | $30.28 | $74.28 | x |
| 2007-12-31 | $41.99 | $74.28 | x |
| 2008-12-31 | $18.23 | $74.28 | x |
| 2009-12-31 | $16.79 | $74.28 | x |
| 2010-12-31 | $10.46 | $74.28 | x |
| 2011-12-31 | $13.84 | $74.28 | x |
| 2012-12-31 | $7.77 | $74.28 | x |
| 2013-12-31 | $8.08 | $74.28 | x |
| 2014-12-31 | $12.65 | $74.28 | x |
| 2015-12-31 | $13.85 | $74.28 | x |
| 2016-12-31 | $14.66 | $74.28 | x |
| 2017-12-31 | $15.13 | $74.28 | x |
| 2018-12-31 | $16.76 | $74.28 | x |
| 2019-12-31 | $17.67 | $74.28 | x |
| 2020-12-31 | $16.36 | $74.28 | x |
| 2021-12-31 | $28.48 | $74.28 | x |
| 2022-12-31 | $20.82 | $74.28 | x |
| 2023-12-31 | $25.15 | $74.28 | x |
| 2024-12-31 | $22.18 | $74.28 | x |
| 2025-12-31 | $25.47 | $74.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ANI Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.49%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.87%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 2.66x
- Recent ROE (14.49%) is above the historical average (-57.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -101.06% | -2161.05% | 0.04x | 1.31x | $-2.92 Million |
| 1999 | -25.80% | -140625900.00% | 0.00x | 1.06x | $-1.95 Million |
| 2000 | -161.70% | -171859750.00% | 0.00x | 1.44x | $-3.65 Million |
| 2001 | -64.45% | -149.44% | 0.35x | 1.23x | $-3.02 Million |
| 2002 | -82.42% | -134.47% | 0.48x | 1.27x | $-4.27 Million |
| 2003 | -68.62% | -9099.08% | 0.01x | 1.10x | $-6.83 Million |
| 2004 | -75.48% | -15427.94% | 0.00x | 1.12x | $-13.61 Million |
| 2005 | -141.53% | -3735.63% | 0.03x | 1.40x | $-10.33 Million |
| 2006 | 15.45% | 19.33% | 0.65x | 1.24x | $984.15K |
| 2007 | -25.51% | -1538.26% | 0.02x | 1.05x | $-10.56 Million |
| 2008 | -126.03% | -460.88% | 0.21x | 1.28x | $-18.81 Million |
| 2009 | -300.23% | -3777.88% | 0.03x | 2.30x | $-49.11 Million |
| 2010 | -241.27% | -1867.09% | 0.06x | 2.34x | $-48.11 Million |
| 2011 | -136.48% | -11859.66% | 0.01x | 1.65x | $-55.39 Million |
| 2012 | -98.38% | -1204.73% | 0.06x | 1.38x | $-30.54 Million |
| 2013 | 0.73% | 1.00% | 0.68x | 1.09x | $-3.80 Million |
| 2014 | 20.57% | 51.36% | 0.21x | 1.89x | $14.77 Million |
| 2015 | 9.60% | 20.14% | 0.27x | 1.78x | $-633.20K |
| 2016 | 2.32% | 3.06% | 0.40x | 1.90x | $-13.03 Million |
| 2017 | -0.62% | -0.61% | 0.43x | 2.36x | $-18.55 Million |
| 2018 | 7.85% | 7.69% | 0.47x | 2.18x | $-4.23 Million |
| 2019 | 2.86% | 2.95% | 0.45x | 2.15x | $-15.19 Million |
| 2020 | -11.52% | -10.82% | 0.45x | 2.36x | $-42.12 Million |
| 2021 | -11.88% | -19.71% | 0.28x | 2.15x | $-78.48 Million |
| 2022 | -14.15% | -15.14% | 0.42x | 2.25x | $-81.75 Million |
| 2023 | 4.10% | 3.86% | 0.54x | 1.98x | $-26.98 Million |
| 2024 | -4.32% | -3.01% | 0.48x | 3.00x | $-61.38 Million |
| 2025 | 14.49% | 8.87% | 0.61x | 2.66x | $24.26 Million |
Industry Comparison
This section compares ANI Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANI Pharmaceuticals Inc (ANIP) | $540.72 Million | -101.06% | 1.66x | $1.41 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |